STOCK TITAN

Exact Sciences Corp - EXAS STOCK NEWS

Welcome to our dedicated page for Exact Sciences news (Ticker: EXAS), a resource for investors and traders seeking the latest updates and insights on Exact Sciences stock.

Exact Sciences Corporation (EXAS) delivers innovative cancer diagnostics through products like Cologuard® and Oncotype DX®. This page provides investors and healthcare professionals with essential updates on the company’s advancements in early cancer detection.

Find curated press releases and news covering financial results, regulatory milestones, product innovations, and strategic partnerships. Our repository ensures timely access to developments impacting precision oncology and noninvasive screening technologies.

Stay informed about EXAS’ role in molecular diagnostics, including updates on clinical studies, technology licensing agreements, and market expansion efforts. All content is verified for accuracy and relevance to support informed decision-making.

Bookmark this page for streamlined access to Exact Sciences’ latest developments. Check back regularly for authoritative updates directly affecting the future of cancer screening and diagnostic solutions.

Rhea-AI Summary

Exact Sciences (NASDAQ: EXAS) has secured the 2024 Great Place To Work® certification, marking the sixth consecutive year of achieving this distinction. This certification is based on a confidential survey of U.S.-based employees, with 85% affirming it as a great workplace, significantly higher than the national average. The recognition underscores the company's commitment to fostering a positive work environment characterized by integrity, teamwork, and innovation. Sarah Condella, EVP of Human Resources, attributes this achievement to the dedication and commitment of the team. The Great Place To Work certification is a testament to the company's efforts in employee retention and innovation, driven by a culture of trust, respect, and collaboration.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.06%
Tags
none
-
Rhea-AI Summary

Exact Sciences Corp. (Nasdaq: EXAS) announced that a judge has denied part of Geneoscopy's motion to dismiss a patent infringement lawsuit. This ruling allows Exact Sciences to move forward with its claims of patent infringement and false advertising. The lawsuit, first filed in November 2023, aims to protect Exact Sciences' Cologuard colorectal cancer screening test from Geneoscopy's alleged infringement and misleading advertising of its ColoSense test. A second complaint was filed by Exact Sciences in May 2024, asserting a new patent related to their sample collection technologies. The company expects the new case to follow a similar timeline to the existing one.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.94%
Tags
none
-
Rhea-AI Summary

Exact Sciences Corp. (Nasdaq: EXAS) reported first-quarter 2024 revenue of $638 million, a 6% increase from the previous year. The company highlighted revenue growth in both Screening and Precision Oncology segments. Exact Sciences also published positive test results in The New England Journal of Medicine and maintained full-year revenue guidance. Despite revenue growth, the company reported a net loss and negative EBITDA for the quarter.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.96%
Tags
Rhea-AI Summary

Exact Sciences Corp. (EXAS) presented six abstracts at Digestive Disease Week 2024, focusing on improving colorectal cancer screening rates. The company showcased data on Cologuard®, a non-invasive screening test, and the upcoming Cologuard Plus™. These advancements aim to enhance patient outcomes by emphasizing effective detection rates and user convenience. The research can potentially address the critical gap in colorectal cancer screening in the U.S.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.06%
Tags
none
-
Rhea-AI Summary

Exact Sciences Corp. will participate in the BofA Securities Health Care Conference in Las Vegas, with a fireside chat scheduled for May 15, 2024. Investors are invited to join the webcast available on the company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.11%
Tags
conferences
-
Rhea-AI Summary
Exact Sciences appoints Aaron Bloomer as new Chief Financial Officer, bringing over 15 years of finance and accounting experience from companies like Baxter International and 3M. Bloomer's global expertise in setting corporate strategy and driving growth will aid Exact Sciences in expanding its cancer screening and diagnostic tests portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.4%
Tags
none
Rhea-AI Summary
Exact Sciences Corp. announced a $620.7 million exchange of Convertible Senior Notes, issuing new 1.75% Convertible Senior Notes due 2031. The transaction involves the retirement of $359.7 million Existing Notes and $266.8 million in cash. The New Notes mature on April 15, 2031, with an interest rate of 1.75% per year. Conversion options include cash, common stock, or a combination, with redemption possible after April 17, 2029, under certain conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.88%
Tags
none
-
Rhea-AI Summary
Exact Sciences Corp. presents groundbreaking data from ASCEND-2 study on multi-cancer early detection blood test at AACR 2024, showcasing high detection rates and specificity across various cancer types. The study affirms the potential of MCED tests to revolutionize cancer screening by identifying aggressive cancers and those lacking standard screening tests early on.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.57%
Tags
conferences
-
Rhea-AI Summary
Exact Sciences Corp. (EXAS) to release its first quarter 2024 financial results on May 8, 2024. The company will host a webcast and conference call to discuss financial results and business progress.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.57%
Tags
Rhea-AI Summary
Exact Sciences partners with Mayo Clinic to offer comprehensive genomic profiling and hereditary cancer tests, enhancing cancer research and patient care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.65%
Tags
none
Exact Sciences Corp

Nasdaq:EXAS

EXAS Rankings

EXAS Stock Data

8.22B
183.06M
1.07%
100.78%
5.74%
Diagnostics & Research
Services-medical Laboratories
Link
United States
MADISON